New hope for rare nerve disorder: drug combo trial targets mobility
NCT ID NCT05939037
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tests whether adding zanubrutinib to standard rituximab therapy can improve walking and arm function in people with nerve damage from a blood condition called IgM MGUS. About 35 adults will receive the combination for up to 12 months, with follow-up over 3 years. The goal is to see if the treatment helps reduce disability and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Medical Center Utrecht
Utrecht, Utrecht, 3584CX, Netherlands
Conditions
Explore the condition pages connected to this study.